Breast Diseases Clinical Trial
Official title:
Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection
NCT number | NCT02566499 |
Other study ID # | B2015:73 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2018 |
Est. completion date | December 2019 |
Verified date | May 2019 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main goal of this project is to assess the ability of a recently developed Breast Microwave Imaging (BMI) system to detect abnormalities in a human breast. These trials will be performed by recruiting fourteen volunteers that have been diagnosed with breast abnormalities using x-ray mammography. The breast presenting the abnormality will be imaged using the BMI system in a controlled and comfortable environment. As this is a feasibility study of the technology, and has the main goal to evaluate the diagnostic accuracy of this technology. The data collected from this study will be used to: (1) evaluate the overall participant experience during the BMI imaging procedure, (2) optimize the design of the BMI imaging system (both hardware and software), (3) open discussions with other medical professionals (e.g. radiologists) about the clinical feasibility of this emerging diagnostic imaging modality.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2019 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years to 85 Years |
Eligibility |
Inclusion Criteria: - The volunteers must be at least 40 years old. - The volunteers should have been diagnosed with a breast abnormality using x-ray mammography within the preceding two months. Exclusion Criteria: - The volunteers should not have breast implants. - The volunteers should have not yet had a biopsy. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic Accuracy (NO units) | Diagnostic Accuracy = (TP+TN)/(TP+FP+FN+TN): The fraction of patients that are diagnosed accurately, which is in turn a function of the Sensitivity and Specificity of the test. Sensitivity: The probability that a test result will be positive when the disease is present (true-positive fraction) = TP/(TP+FN) Specificity: The probability that a test result will be normal when the disease is absent (true-negative fraction) = TN/(FP+TN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative |
1 year | |
Secondary | Sensitivity (NO units) | Sensitivity: The probability that a test result will be positive when the disease is present (true-positive fraction) = TP/(TP+FN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative |
1 year | |
Secondary | Specificity (NO units) | Specificity: The probability that a test result will be normal when the disease is absent (true-negative fraction) = TN/(FP+TN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative |
1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04854304 -
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
|
||
Recruiting |
NCT01678170 -
Clinical Application of Breast Blood-oxygen Functional Imaging Technology
|
N/A | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04535466 -
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
|
||
Recruiting |
NCT01917279 -
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
|
Phase 3 | |
Recruiting |
NCT01427400 -
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
|
Phase 4 | |
Completed |
NCT05665894 -
Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis
|
||
Not yet recruiting |
NCT04088110 -
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
|
Phase 2 | |
Terminated |
NCT02997540 -
Effect of Body Position and Probe Position on the Localization of Breast Mass
|
||
Terminated |
NCT01140776 -
Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy
|
N/A | |
Recruiting |
NCT04911101 -
Performance Indicators and Patient Experience in 7G and 10G Vacuum-assisted Excision of Probably Benign Breast Lesions
|
N/A | |
Completed |
NCT04554316 -
Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery
|
N/A | |
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Completed |
NCT03743259 -
To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions
|
Phase 2 | |
Recruiting |
NCT04605575 -
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
Completed |
NCT02452333 -
Oncoplastic Approach to Excisional Breast Biopsies
|
N/A | |
Terminated |
NCT01372215 -
Multi-Compression Spot Mammography
|
N/A | |
Completed |
NCT00299039 -
T3AI-Pain After Breast Surgery
|
Phase 3 |